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Abstract
Background: It is increasingly recognized that non-motor symptoms are a prominent feature of Parkinson’s disease and in
the case of cognitive deficits can precede onset of the characteristic motor symptoms. Here, we examine in 4 monkeys
chronically treated with low doses of the neurotoxin MPTP the early and long-term alterations of rest-activity rhythms in
relationship to the appearance of motor and cognitive symptoms.
Methodology/Principal Findings: Behavioral activity recordings as well as motor and cognitive assessments were carried
out continuously and in parallel before, during and for several months following MPTP-treatment (12–56 weeks). Cognitive
abilities were assessed using a task that is dependent on the functional integrity of the fronto-striatal axis. Rest-activity
cycles were monitored continuously using infrared movement detectors of locomotor activity. Motor impairment was
evaluated using standardized scales for primates. Results show that MPTP treatment led to an immediate alteration (within
one week) of rest-activity cycles and cognitive deficits. Parkinsonian motor deficits only became apparent 3 to 5 weeks after
initiating chronic MPTP administration. In three of the four animals studied, clinical scores returned to control levels 5–7
weeks following cessation of MPTP treatment. In contrast, both cognitive deficits and chronobiological alterations persisted
for many months. Levodopa treatment led to an improvement of cognitive performance but did not affect rest-activity
rhythms in the two cases tested.
Conclusions/Significance: Present results show that i) changes in the rest activity cycles constituted early detectable
consequences of MPTP treatment and, along with cognitive alterations, characterize the presymptomatic stage; ii) following
motor recovery there is a long-term persistence of non-motor symptoms that could reflect differential underlying
compensatory mechanisms in these domains; iii) the progressive MPTP-monkey model of presymptomatic ongoing
parkinsonism offers possibilities for in-depth studies of early non-motor symptoms including sleep alterations and cognitive
deficits.
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Introduction
Parkinson’s syndrome (PS) was initially characterized by motor
symptoms including rigidity, akinesia and tremor. However, it is
increasingly recognized that these motor deficits are accompanied
in88%ofPSpatients bysymptomsaffectingcognitiveperformance,
neuropsychiatric states, sleep, autonomic, and sensory domains
which are important factors contributing to physical and mental
disability [1,2,3,4]. These non-motor symptoms have important
consequences contributing to a decline in the quality of life. The
causes of non-motor manifestations of PS could be multifactorial
and related to widespread neurodegenerative processes of both
dopaminergic and non-dopaminergic systems [5].
While numerous studies using animal models of Parkinson’s
disease (PD) have explored different aspects of these non-motor
deficits, there is to date a lack of information concerning their
overall orchestration with respect to the onset of classical clinical
disease. We have therefore conducted a longitudinal study to
simultaneously evaluate the temporal patterns of alterations in
rest-activity cycles and cognition in the MPTP monkey model of
PS.
The compensatory mechanisms and the concealed or partially
concealed deficits that appear early on in PS, when the brain is
undergoing major alterations during the pre-symptomatic period,
are still not fully understood [6]. A long-standing literature has
established that a low-dose MPTP regime in the monkey can
induce long-lasting cognitive deficits resulting from fronto-striatal
dysfunction, independent of the manifestation of any clinical signs
of motor dysfunction [7,8,9,10]. Other studies have shown that
high doses of MPTP that rapidly engender severe clinical motor
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ever, it is not known if the impact of the dopaminergic lesion on
biological rhythms occurs independently of either motor and/or
cognitive effects during the so called pre-symptomatic period in
which cognitive deficits are typically reported [12,13].
While Parkinsonism is currently viewed as a complex network
disorder [14], there is need for a more complete understanding of
the spectrum of changes in PS that precede the diagnosis of
classical motor deficits. This information is crucial for developing
more effective and specific means of detecting disease onset as well
as designing more effective therapeutics for the full range of
symptoms. It follows that long term multi-dimensional survey of
neurobiological states during the early stages of development of
PS would be a valuable prerequisite for gaining a better under-
standing of the diagnostic features and timing of the different
physiopathological components.
We therefore used continuous, long-term recordings in a non-
human primate model of PS to analyze in parallel the changes in
clinical scores, cognitive task performance and locomotor rest-
activity patterns. We used chronic low-dose injections of MPTP to
induce a Parkinson-like state that includes the development of
compensatory mechanisms, thereby providing a model of low-
grade dopaminergic lesion and sub-threshold clinical states [6].
Importantly, injections were suspended upon reaching a specific
clinical threshold thereby favoring spontaneous motor recovery.
However, analysis of behavioral parameters before, during and
after chronic low-dose MPTP treatment demonstrated clear
dissociations between clinical manifestations of motor dysfunction
and both rest activity cycles and cognitive performances.
Materials and Methods
Ethics Statement
All procedures were carried out according to the 1986
European Community Council Directives (86/609/EEC), the
French Ministe `re de l’Agriculture et de la Fore ˆt, French
Commission of animal experimentation, the Department of
Veterinary Services (DDSV Lyon, France). These experiments
were also carried out according to guidelines published in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. Under local rules, authorization is granted to
the laboratory for a range of experiments, rather than for specific
studies. Specific authorization covering this study was delivered by
the ‘‘Pre ´fet de la Re ´gion Rho ˆne Alpes’’ and the ‘‘Directeur
de ´partemental de la protection des populations’’ under Permit
Number: #A690290402, including approved protocols in NHPs
(#047, #048, #0198, #0199, #0200). All procedures complied
with guidelines for animal welfare in accordance with the recom-
mendations of the Weatherall report, ‘‘The use of non-human
primates in research’’. The nature of the measures and inter-
ventions described below required individual housing of monkeys
during the experiment. This is also a welfare measure – sympto-
matic MPTP-treated monkeys would be at risk of persecu-
tion in a group-housing situation. Given this, however, all efforts
were made to provide an enriched and social environment for the
animals in a colony room with other familiar monkeys. All
monkeys were closely monitored on a regular basis throughout the
day, by several researchers as well as animal care staff, in order to
ensure that levels of health and welfare were maintained. This was
particularly the case during the MPTP period. As required,
adaptations to housing and feeding procedures were made in
direct response to individual symptoms in the MPTP phase, for
example adaptations of water provision to ensure monkeys were
able to drink ad libitum throughout.
Animals and housing
Four monkeys were studied: three female Macaca fascicularis
(monkeys J, F and L; aged respectively of 15, 12 and 11 years old)
and a 13-year old male Macaca mulatta (monkey T), weighting 6,
5.5, 4.7 and 12kg, respectively. Animals were housed in a room
dedicated to MPTP experiments, had free access to water and
received food twice a day. Illumination was provided by white
fluorescent tubes (Phillips Master, 15 Watts) mounted on the
ceiling above the animal’s cage providing 450–500 lux depending
on the animal’s position and gaze inside of the cage. The lighting
schedule was clock-controlled for 14 hours light - 10 hours dark
(14:10 LD) for monkeys J and T and 12 hours light - 12 hours
dark (12:12 LD) for monkeys L and F. Mean room temperature
during data collection was maintained at approximately 24–26uC.
MPTP intoxication
A protocol of chronic low-doses (CLD) injections of 1-methyl-4-
phenyl 1,2,3,6-tetrahydropyridine (MPTP) was employed based
on previous studies [15] in order to obtain a slow onset of
symptoms. CLD-MPTP treatment consisted of intramuscular
injections of MPTP-HCl (Sigma M0896) diluted in sterile water
at a concentration of 0.2 mg/kg. Injections were performed every
3 to 4 days in the home cage, without prior sedation. Pre-diluted
doses of MPTP were prepared and stored in single-dose syringes
(Myjector, TerumoH)a t280uC. The storage period did not
exceed 2 months since MPTP can become unstable over longer
periods [16]. NIH safety guidelines were respected for housing of
treated-animals, MPTP preparation, storage, injection, and
elimination. Injections of sterile water alone were performed
previously to MPTP administration to ensure the absence of effects
of injection procedure on measured behavioral parameters. As
these animals were part of an ongoing study, they were not
sacrificed at the end of the recordings and thus the extent of
induced lesion on the aminergic system could not be verified. In
one case (L), the levels of DA transporters was evaluated in-vivo in
a follow-up PET study using a specific radioligand ([11C]-PE2I,
[17]). Moreover, the cumulated doses used here (.2mg/kg) were
superior to minimal cumulated dose used in previous studies that
resulted in significant insult to the DA system [6,18].
Clinical Motor Evaluation
A clinical rating scale: the Parkinsonian Monkey Rating Scale
(PMRS), adapted from the Unified Parkinson’s Disease Scale
(UPDRS) used for patients and compatible with rating scales used
for monkeys [19], was employed to define the onset of the
symptomatic period and to determine when to cease MPTP injec-
tions at the appropriate level of symptoms. We used the subtotal
score of the PMRS corresponding to previously described scoring
criteria in monkeys [20]: a score of 0 defined the asymptomatic
stage; a score between 1 and 5 defined the pre-symptomatic period;
a score above 5 defined the symptomatic stage. Once monkeys
entered the symptomatic stage, injections were halted in order to
gain information about possible spontaneous recovery. Clinical
symptoms were assessed daily and the total score for freezing (0–3),
resting tremor (0–3, for right and left side), rigidity (0–3), posture (0–
2), bradykinesia (0–3), and ability to manipulate food (0–3, for right
and left side) was used to frame injections (maximum total score of
23).
Cognitive Behavioral task
Cognitive performance was monitored 5 days a week using a
behavioral test previously employed to assess fronto-striatal func-
tions and post-MPTP cognitive deficits [7,8,10]: Object Retrieval
Non-Motor Symptoms in CLD MPTP-Monkey
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animal’s home cage and prior to injections during the MPTP
period. Monkeys had to retrieve within a delay of 1 min a piece of
fruit placed in a transparent box with an opening for access placed
on only one side. Animals were tested for detour trials (see Figure
S3) in which the open side was not facing the animal (either right
or left side), requiring inhibition of the tendency to reach directly
toward the reward and instead a strategy of a detour reach.
However, each testing session contained a third of trials with the
open side facing the animal so that the required reach was straight
forward, in order to avoid automatic responses. Performance was
evaluated by measuring successes and errors on detour trials.
Successes (retrieval of reward on the first reach) were expressed as
percentage of total number of trials. Errors (barrier hits i.e. hitting
a transparent side of the box) were expressed as percentage of
responses observed (there could be several responses per trial
except in the case of success). A maximum of 18 trials per session
were presented randomly to the animal each day. Animals initially
received a short period of training to become accustomed to the
presence of the experimenter and to learn the task; performance
was then evaluated.
Rest-wake activity profiles
Locomotor activity was recorded in the home cage (actimetry),
continuously throughout the entire duration of the study (up to 16
months). Animal movements were detected using passive infrared
captors placed above the cage and a monitoring system developed
in the laboratory (Circadian Activity Monitoring System, CAMS,
Inserm; see [21]). The captors detect the animal’s displacements in
the cage but are not sensitive to small tremor. Signals from the
captors were recorded continuously and stored in 1 min bins
(counts/min). The quantified activity thus represents spontaneous
locomotor displacements throughout the rest-activity cycle.
Monkeys were maintained in a 14:10 or 12:12 light: dark cycle.
Maximum light intensity was 400 lux (Fluorescent white light
4000K) during the daytime period and 0 lux at night.
L-Dopa treatment
A short-term dopatherapy was scheduled in cases J and T in
order to investigate effects on: i) cognitive performances, and ii)
circadian expression of locomotor rhythms post-MPTP. During
the period of these tests (3–4 weeks), monkeys were treated twice-
daily with oral administration of levodopa (SinemetH, levodopa:-
carbidopa - ratio 10:1) at a dose designed to produce a full reversal
of the parkinsonian condition (15–20 mg.kg
21 of body weight;
[22]). This was not carried out on cases L and F because they
entered a cellular therapy protocol that will not be described here.
Data analysis
We segmented MPTP and recovery periods into 4 equal epochs,
5 quantiles were then calculated from the beginning of each period
using a 1-D linear interpolation method (MatLab interp1 function,
de Boor, C. (1978) A Practical Guide to Splines. Springer-Verlag).
These quantiles allowed a comparison of the time course of the
variations of different parameters across an equivalent number of
epochs for all subjects. This method of segmentation thus com-
pares the stages of progression of processes linked to the aminergic
lesion according to the behavioral outcomes rather than based on
an absolute time-scale. Non-parametric circadian rhythm analysis
(NPCRA) was used to extract actigraphic variables from diurnal
activities [23]. These included measurements of (1) intra-daily
stability (calculated as the variance of the average 24-hr pattern of
activity around the mean and overall variance, indicating the
consistency of day to day activity or the strength of coupling to the
LD cycle i.e. the synchronizer) (2) intra-daily variability (indicating
the frequency of transitions between rest and activity periods,
corresponding to the fragmentation of activity) and (3) relative
amplitude (ratio between the acrophase and the nadir of the
rhythm, representing the ratio between the amplitude of activity in
the light and dark phases). When the rest-activity cycle is stable,
intra-daily stability is high, intra-daily variability is low (low
fragmentation), and relative amplitude is high. Cognitive and
clinical scores were also analyzed for the same quantile epochs
using the same method to facilitate comparison between these
three sets of scores.
Statistics
Results are presented as means 6 standard errors. Each
monkey’s weekly performance was compared with control by a
treatment-contrast test using control measures as the first level
(estimated standard errors and z-ratio were computed using GLM
fit and contrast result was given by two-tailed p-values corre-
sponding to z-ratio based on a Student t-test). Significance was
considered for p,0.05. Statistical analyzes were computed using
the R software (R Foundation for Statistical Computing, Vienna,
Austrian http://www.R-project.org) and the summary function
(Chambers, J. M. and Hastie, T. J. (1992) Statistical Models in S.
Wadsworth & Brooks/Cole).
Results
Clinical score, cognitive performance in a detour reaching task,
and rest-activity cycles were followed continuously before, during
and after MPTP-treatment for a period of up to 16 months in each
of four macaque monkeys. While there was considerable
variability in the sensitivity of individual animals to the CLD-
MPTP treatment, the repeated sub-acute injections of MPTP
reproduced non-motor symptoms typical of PS. The relative
timing of the changes in rest activity and cognitive symptoms with
respect to the onset of clinical motor symptoms were similar
among all cases. In one case motor deficits persisted after MPTP
treatment cessation and here cognitive and chronobiological
deficits could not be dissociated. However, we observed long
lasting non-motor symptoms in all cases studied and importantly
in the three cases where there was recovery from motor deficits.
Motor symptoms
All monkeys presented a clinical motor score of 0 in control
conditions (Parkinsonian Monkey Rating Scale – PMRS, see
materials and methods section) and after injections of sterile water.
Figure 1 represents changes in clinical scores of all cases studied
aligned at the end of MPTP-treatment. Despite the different
durations of MPTP intoxication required to attain clinical
threshold and the different scores attained after MPTP-Off, the
three monkeys that spontaneously recovered (cases J, T and F)
presented relatively similar temporal dynamics of motor recovery
(within 5–7 weeks). In case J the first clinical manifestation was
observed 3 weeks after the onset of MPTP treatment and
symptoms progressively increased up to 7 weeks when threshold
(clinical score .5) was reached defining a pre-symptomatic period
of 6 weeks, for a total cumulative dose of 2.2 mg/kg (Figure 2A,
left). For case T, the onset of clinical symptoms occurred at 4
weeks and threshold was achieved at 28 weeks so that the pre-
symptomatic period lasted considerably longer than in other cases
(Figure 2A, right). In case T, we observed a marked but small
peak in the clinical score at week 6 of treatment consisting of slight
resting tremor (low amplitude and only intermittently present in
the upper limbs). Given the weak response to MPTP in this case,
Non-Motor Symptoms in CLD MPTP-Monkey
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cumulative dose of 10.4 mg/kg). In case F, clinical symptoms also
appeared 5 weeks after the beginning of MPTP-treatment and
remained stable and low (i.e. score,5) for the 4 following weeks
(Figure 3A, left), here MPTP treatment was therefore increased
from week 10 onwards, which led to a progressive increase of
symptoms until week 12, when the clinical threshold was reached.
The pre-symptomatic period in this case lasted 11 weeks for a total
cumulative dose of 5.4 mg/kg. In case L, clinical symptoms
emerged 5 weeks after initiation of treatment and increased
continuously to reach threshold at week 9 (Figure 3A, right) for
a total cumulative dose of 4.4 mg/kg and a pre-symptomatic
period of 8 weeks, note that here the regimen of MPTP-injection
was also increased in the last 3 weeks of intoxication.
Clinical symptoms emerged in the following order: action and
resting tremor, bradykinesia, rigidity, stooped posture and freezing
for cases J and L; action tremor, bradykinesia, stooped posture,
resting tremor and freezing for case F; action tremor, bradykinesia,
stooped posture, freezing and resting tremor for case T. The
symptomatic period defined by a clinical score $5 lasted 17 days
for case J, 24 days in case F and 6 days for case T. In case L, the
symptomatic period lasted more than 12 weeks, this animal
remained symptomatic after MPTP-Off with no spontaneous
recovery. In this case, we confirmed that the lesion induced by
MPTP progressed further than the critical threshold of 70–80% of
striatal denervation [24], as shown by a separate study of DA
transporter using PET-imaging with a specific radioligand ([11C]-
PE2I, [17]). This showed that striatal denervation was .80% as
estimated by binding potential calculation [25] two months after
MPTP cessation (data not shown).
For the other cases (J, F and T) spontaneous recovery was
consistently observed with clinical scores decreasing progressively
after 1 to 5 weeks of symptomatic state (Figure 2A, 3A). In case J
some minor, transient bouts of motor symptoms were also
observed around weeks 20 and 33 post-treatment. Following the
last MPTP injection, recovery was observed in 6 weeks in case J, 5
weeks in case F and 7 weeks in case T.
Case J presented a persistent but slight action tremor of the
upper limbs, which is not taken into account in PMRS scoring.
This action tremor in case J was present throughout the pre-
symptomatic period, stress enhanced and clearly visible during
precise grasping movements. Levodopa treatment alleviated this
condition by reducing action tremor amplitude and occurrence in
the first week and making it rare to undetectable during the
following weeks of therapy. It reappeared one week after levodopa
offset. Case T presented a clinical score of 0 and no clear action
tremor from week 35 onwards. In case T the only abnormality
observed was a depressed-like behavior the week following
levodopa offset (with little or no motivation to work for rewards).
Case F presented a persistent slight bradykinesia throughout the
rest of the protocol with a score of 1 (Figure 3A, left); L-Dopa
was not tested in this case (see the material and methods, L-Dopa
treatment section for details).
The clinical score variations for all cases when calculated
according to quantile segmentation (see below), showed very
similar sequential patterns over the intoxication and recovery
periods, despite the individual differences in sensitivity to MPTP,
in respect to both duration of effects and dose response.
Cognitive Performances
Following one month of initial training, control performances in
the detour reaching task (testing capacity to inhibit erroneous
actions, see methods for further details) were averaged over the
week preceding MPTP injections. Monkeys made relatively few
errors and attained success rates of 60–80% (Mean 6 SD; Case J:
success rates 57636%, error rates 17615%; case T: success rates
69625%, errors rates 30623%; Case F: success rates 8167%,
error rates 2368%; Case L: success rates 6869%, error rates
24610%; Figure 2B,C and Figure 3B,C).
For case J, MPTP performance was significantly worse than in
the control conditions starting from the 2
nd week of injections
(p,0.05, with Z-value,22.4 for success and Z-value.2.3 error
rates; Figure 2B,C left). The balance between error and success
rates observed during the control period gradually reversed to an
absence of success and an large increase of errors (more than 50%)
at the end of MPTP intoxication (week 6). These poor perfor-
mance levels, reminiscent of frontal-like behavior, remained con-
stant even aftertheinjections were terminated (p,0.05,Z-value,22.1
Figure 1. Progression of Clinical Scores in MPTP treated monkeys. Weekly clinical measures (mean 6 SEM) for all monkeys aligned on MPTP
treatment cessation (MPTP-Off). The shaded area corresponds to the symptomatic stage. During chronic low dose MPTP intoxication (MPTP) and prior
to attaining the clinical threshold of 5, monkeys are considered as presymptomatic. After MPTP-Off, 3 monkeys spontaneously recovered to a non-
symptomatic stage within 1–4 weeks while 1 monkey remained in a mild-symptomatic stage. Arrowheads in red indicate the time of MPTP onset for
each animal.
doi:10.1371/journal.pone.0023952.g001
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Figure 2B,C left).
For case T, performance in the first week of intoxication up to
week 7 was significantly worse than during the control period
(p,0.001, Z-value,23.8 for success rate and p,0.05, Z-
value.2.1 for error rate; Figure 2B,C right). During the
remaining weeks of intoxication (week 8–27) performance
continued to be globally worse than during the control period
(Figure 2B,C right). After MPTP injections were terminated,
case T recovered a control level of performance, except during the
first week following MPTP-Off (p,0.01, with Z-value,23.4 for
success and Z-value.5.2 for error rates).
For case F, the first week of intoxication led to an abrupt
decrease of performance and a return to control values in the 2
nd
week (Figure 3B,C left). Subsequently performance deteriorated
significantly with respect to the control condition and we observed
again a reversal of the balance between success and errors. Success
rate decreased and error rate increased progressively to reach
maximum values at week 9 (p,0.001, with Z-value,24.9 for
success and Z-value.4.6 for errors). During the course of the
MPTP-treatment, monkey F was sometimes reluctant to work for
rewards and this was identified as a lack of motivation since
generally monkey F would reach for fruit when offered outside the
context of the task. Performance remained significantly worse than
Figure 2. Evolution of behavioral parameters throughout the entire protocol. Weekly behavioral measures (mean 6 SEM) for monkey J, left
and monkey T, right. A. Clinical score variations from PMRS. Note that a score above 5 defines the symptomatic stage (clinical threshold, green line).
B. Percentage of errors (barrier hits, purple) and C. percentage of successes (direct reach, blue) for the detour task (detour trials, see Figure S3).
Performances (successes, errors) during and after MPTP-treatment are compared to control measures (horizontal dashed lines). D. Total daytime
(orange circles) and night time (black squares) locomotor activity counts and associated curves of activity smoothed with the rloess method
(span=0.5). Baseline levels are represented by dotted lines for each behavioral parameter (Ctr day, Ctr night). Stars refer to statistics applied on
Success and Error rates. ns: non-significant,?:p ,0.1, *: p,0.05, **: p,0.01, ***: p,0.001.
doi:10.1371/journal.pone.0023952.g002
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treatment cessation (12 weeks; p,0.05, with Z-value,21.4 for
success and Z-value.0.7 for errors; Figure 3B,C left).
For case L, performance deteriorated significantly from the 5
th
week of injections (p,0.001, with Z-value,23.5 for success and
Z-value.2.7 for errors); but was noticeably altered beginning with
the 1
st week of MPTP injections (Figure 3B,C right). In case L
in the last weeks of MPTP-treatment the balance between success
and errors was totally reversed (success rates 31610%, error rates
59612%). Because of a persistent, mild-parkinsonian state in case
L, trial number per session for behavioral tests was reduced
following MPTP-Off but was sufficient to show that performance
remained constantly worse than in the control period (p,0.01,
with Z-value,22.1 for success and Z-value.1.9 for errors).
For case J, levodopa therapy improved performance (success
rate .30%, error rate ,50%; Figure 2B,C left) but did not
allow recovery up to control levels. Performance for case T during
levodopa therapy was better than during control (zero errors and
100% success rate throughout the 3 weeks of levodopa treatment;
Figure 2B,C right).
Quantile comparison of error rates revealed similar dynamics
across animals of the increasing difficulties to perform the task
throughout the MPTP intoxication phase (see Quantile Analysis
section). During the recovery period, these difficulties persisted for
Figure 3. Changes of behavioral parameters over MPTP and Recovery periods. Weekly behavioral measures (mean 6 SEM) for monkey F,
left and monkey L, right. A. Clinical score variations from PMRS. B. Percentage of errors (barrier hits, purple) and C. Percentage of successes (direct
reach, blue) at the detour task. D. Total daytime (orange circles) and night time (black squares) locomotor activity counts and associated curves of
activity smoothed with the rloess method (span=0.5). Conventions as for Figure 2.
doi:10.1371/journal.pone.0023952.g003
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than control levels for cases J, F and L) even though clinical scores
had returned to non-symptomatic levels for cases J and F. However,
for the rhesus (case T) the error rate rapidly returned to control
levels.
Rest-activity rhythms
During the initial control period all monkeys presented rest-
activity rhythms that were highly structured and precisely
synchronized with the light-dark (LD) cycle. Animals typically
presented an immediate but progressive onset of activity at lights-
on and an abrupt offset of activity at lights-off. Almost all activity
(95.462%) was confined to the light phase (Figure 4A,C and
Figure S1A,C). For case J, the mean6SD activity was 240.667.8
counts/hour during the day (light phase) and 1260.6 counts/hour
at night (dark phase); for case T, 617.4617.4 counts/hour during
the day and 48.661.2 counts/hour at night; for case F, 260623.1
counts/hour during the day and 23.461.8 counts/hour at night
and for case L, 413.9625.6 counts/hour during the day and
18.363.5 counts/hour at night (Figures 2D, 3D).
The rest-wake activity patterns during MPTP-intoxication are
illustrated on the averaged profiles (Figures 4B,D and Figure
S1B,D). All cases showed an abrupt and immediate change in
rest-activity patterns from the first days of treatment, except in
case L in which alterations were observed after one week of MPTP
intoxication (Figures 2D, 3D). In case J, these changes consisted
of a sustained and abnormally elevated night-time activity
throughout the period of MPTP treatment (Figures 2D, left).
This was also the case for case L during the first 6 weeks of MPTP
treatment (Figures 3D, right). For cases T, F and L, a
progressive decrease in daytime activity was observed. The curves
consistently showed a slight regain of daytime activity levels
around the last third of the whole MPTP treatment period, just
preceding a sharp decrease in activity that accompanied the
invalidating clinical symptoms (Figures 2A,D, and 3A,D).
During the recovery period, rest-activity rhythms remained
abnormally low for cases T, F and L for prolonged periods and
failed to fully return to baseline levels throughout the entire time
course of the observations (.11 months; Figures 2D right, 3D,
4B,D and S1B,D), long after spontaneous recovery from clinical
symptoms. In case L, which failed to recover from motor
symptoms, night time activity increased dramatically after
MPTP-Off (Figures 3D right, and S1C,D).
In the two cases tested with levodopa (cases J and T), rest-
activity rhythms were not affected in contrast to effects on
cognitive performance (Figures 2D and 4A–D).
Figure 4. Locomotor activity rhythms (monkey J): A. 48h double-plot actogram: activity presented over consecutive days (each line is 48h) for
the entire protocol. Daytime and night time periods are delimited by white and black rectangles, respectively (above actogram). Note the strong
synchronization of activity at lights-off. B. 24h average locomotor activity profiles of 3 representative weeks taken over different time-windows of the
protocol (time-window periods indicated on the left of profiles). Note the clear increase of night-time activity during MPTP and the progressive
decrease after MPTP-Off. Locomotor activity rhythms (monkey T): C. 48h double-plot actogram and D. 24h average locomotor activity profiles
(average over 3 representative weeks within the period indicated on the left). Note the clear fragmentation and amplitude decrease of daytime
activity with MPTP intoxication and, the progressive return to near baseline after MPTP-Off.
doi:10.1371/journal.pone.0023952.g004
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behavioral changes
Since the four animals showed different vulnerabilities to the
MPTP treatment resulting in large differences in the time required
to display clinical motor symptoms (6, 8, 11 and 28 weeks), we
analyzed several parameters according to subdivisions of time
periods (quantiles) in order to disclose any similar trends in the
appearance of the non-motor symptoms. This was assayed by
dividing each phase (MPTP and post-MPTP) in an equal number
of epochs. When normalized in this way, the evolution of the
clinical scores during treatment and recovery exhibits similar
patterns (Figure 5A), even though the time required to attain the
critical clinical score of 5 differed significantly between animals
(Figure 1). There was a similar trend in the increase of errors
during treatment. However, during recovery cases J, L and F
showed no post-treatment improvement while case T showed a
sustained reduction in errors (Figure 5B).
All cases showed severely altered values for rest-activity
parameters by the end of the first quantile of the treatment
period, when clinical scores were still at baseline. Analysis of the
intra-daily stability, the relative amplitude and the intra-daily
variability of rest-wake activity revealed that all cases showed
similar patterns of alteration during and after MPTP treatment
(Figure 5C–E), with the exception of case L that showed more
severe alterations. Intra-daily stability of the rest-activity cycle
(representing the strength of coupling of the rest-activity cycle to
the external light-dark cycle [26]) decreased immediately after
initiation of MPTP treatment, and continued to decrease
throughout treatment. For cases J and T stability only returned
to baseline levels several months after MPTP treatment ended
while in cases F and L there was no recovery (case J 8 months and
case T 3 months, Figure 5C). The relative amplitude represents
the strength of the rhythmic oscillation of motor activity and is
obtained by comparing the difference between the most and least
active periods. Relative amplitude was also found to evolve in a
similar manner during recovery for the 3 monkeys (J, T, F;
Figure 5D) only returning to baseline levels months after
treatment (and not at all for monkey L). Intra-daily variability, a
parameter that reflects the fragmentation of activity (i.e. frequency
and extent of transitions between activity and rest) consistently
increased during and after MPTP treatment (Figure 5E). Thus,
this method of comparison showed similar outcomes during and
after MPTP treatment for the spontaneously recovered cases. For
case L, that continued in a symptomatic state, all parameters
remained dramatically affected.
Discussion
We have designed a protocol for chronic multidimensional
characterisation of non-motor aspects of PS. Despite inter-
individual differences, monitoring a range of behavioural param-
eters, our results clearly show that CLD-MPTP induces early and
long-term non-motor features of idiopathic PS (see Table S1 for a
summary of main results). Furthermore, all cases exhibited very
early changes in both rest-activity cycles and cognitive perfor-
mances, virtually immediately after the first MPTP administration
and well before clinical motor symptoms.
A key finding is the demonstration that the MPTP induced
changes in chronobiological parameters constitute a precocious
and consistent feature of the pre-symptomatic phase that precedes
or coincides with measurable cognitive decline (i.e. after the 1
st
MPTP injection in case J and L, the second MPTP injection in
case T and the 6
th injection in case F). Identification of the
temporal sequence of behavioral events (chronobiology, cognitive,
motor) subsequent to MPTP intoxication benefited from several
factors. The within subject experimental design allowed each
animal to serve as its own control, decreasing variability and
increasing the sensitivity of the measures. The long-term,
continuous 24h monitoring of behavior permitted a fine grain
analysis of behavioral decline for several chronobiological
parameters.
Cognitive deficits
The cognitive decline induced by MPTP-intoxication was
typically pre-symptomatic (i.e. before the onset of characteristic
parkinsonian motor symptoms) and persisted after full clinical
recovery. The detour task exploited here is very simple to learn,
easy-to-test, has been used in numerous protocols and is con-
sidered to be dependent on the integrity of frontal cortex, the
dopaminergic system and DA innervation of frontal cortex. For
example, these tests were used by Diamond and Goldman-Rakic
in the 19809s to demonstrate that human infants and infant
monkeys show a clear developmental progression of cognitive
abilities that accompanies maturation of the DA system (see [27]
for a review). Cognitive operations, crucial for planning and
problem solving, are known to be impaired in both parkinsonian
patients and CLD-MPTP monkeys [9,10,28,29]. In monkeys,
cognitive and complex motor planning abilities following MPTP
treatment have previously been tested using various protocols
including extra- and intra-dimensional shifting tasks, delayed
response tasks, Go No-Go tasks, context dependant movement
selection (automated version of the ODRT), multiple choice
retrieval tasks, and the object detour retrieval task [9,10,13,30].
These investigations have shown that cognitive impairments can
occur without clinical symptoms when using low-dose MPTP
injections with, in some cases, maintenance of deficits several
weeks (e.g. [31]) or years after MPTP exposure [32]. Here we
show that the detour task revealed deficits within one to five weeks
of low dose treatment. Previous investigations also reported
cognitive deficits at various delays depending on the injection
protocol [10,13,30]. Inter-individual variability of the onset is
frequently reported. Our day by day examination of cognitive
performance showed the first significant decline to be detectable
after 1
st injection at day 2 in case T, 4
th injection at day 11 in case
J, 2
nd injection at day 4 in case F and after the 5
th injection at day
19 in case L.
The classical DA levodopa therapy protocol clearly improved
performance in cases J and T. In case J the error rate decreased
and the success rate improved to levels that were not significantly
different to those prior to MPTP treatment. In case T, DA
levodopa therapy led to 100% success rates and zero failure rates,
rates that were actually superior to those encountered prior to
MPTP treatment. These results indicate that poor cognitive
performances can be imputed to a dopaminergic deficit in the
brain.
Our results thus confirm previous observations and indicate that
the detour task allows detection of early presymptomatic frontal
behavior deficits during CLD-MPTP and their possible mainte-
nance after clinical recovery.
Chronobiology
Following the MPTP treatment and despite a recovery from
motor symptoms, the rest-activity profiles did not return to a
completely normal state throughout the duration of the experi-
mental observation period. These findings differ from previous
studies of daily activity patterns in MPTP monkeys that mainly
showed (i) a decrease in the overall amount of activity without any
obvious modification of the day-night activity profiles and (ii)
Non-Motor Symptoms in CLD MPTP-Monkey
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23952Non-Motor Symptoms in CLD MPTP-Monkey
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23952changes in rest-activity uniquely when clear motor symptoms were
present [33]. This latter finding differs from our results where
changes in activity profiles are found in the presymptomatic stage.
These differences with our results may be due to the mode of
intoxication (i.e. intravenous injections of MPTP with twice the
concentration compared to what we used), the age of monkey used
(3 years old i.e. juvenile) and the lack of pre-intoxication control
measures from the same monkey. Intravenous MPTP-treatment,
corresponding to an acute intoxication is known to be much more
offensive towards the DA system and induces a different topography
of the DA lesion within basal ganglia [34]. It has also been shown
that older monkeys aremore suitable to reproducethe characteristic
featuresofthisage-relateddisease[35,36].Ourresultsareconsistent
with those of Barraud et al. (2009) [11] that showed a long-term
disruption of sleep–wake architecture and a reduced sleep efficiency
that can be observed years after MPTP administration in monkeys
suffering from chronic clinical motor symptoms following MPTP
administration.
The present findings extend the observations of others by
showing that alterations of the locomotor activity rhythm can
persist in the absence of stable clinical symptoms and are not
necessarily correlated with the degree of motor disability [11,33].
The persistence of activity alteration is particularly evident in the
quantile analyses. The quantile analysis allows a representation of
the behavioral effects during the different periods according to the
experimental stages rather than on their durations and provides a
means to equate the behavioral changes independent of the time
required to attain the clinical criteria. This analysis shows that
despite the different effects on day and night time activities
following motor recovery, all cases presented similar dynamics in
the deterioration of the stability, amplitude and variability of the
rest-wake cycle.
Alterations in sleep, including excessive daytime sleepiness, sleep
fragmentation and rapid eye movement (REM) sleep deregulation
are observed in MPTP treated monkeys [11] and in PD patients
during early and symptomatic stages of the disease [37]. In
humans, actigraphy is routinely used to detect circadian rhythm
disorders [38]. The technique has also been validated against
polysomnography to assess the quality and fragmentation of sleep
and wakefulness [39,40]. Although in monkeys actigraphy has not
been compared to polysomnography, it is likely that, as in humans,
an increase in motor activity during the night time is a marker of
sleep disturbance, and that a decrease in activity during the
daytime could be a sign of daytime sleepiness, in agreement with
Barraud et al. (2009) [11]. These two changes in activity that we
observed during both the presymptomatic and symptomatic
phases, could therefore mimic the patterns of sleep fragmentation
and excessive daytime sleepiness observed in PD patients [41].
The origin of these rest-activity (or sleep) disturbances in MPTP
monkeys is still a matter of speculation. In MPTP treated monkeys
some studies e.g. [42] have reported loss of dopaminergic as well as
other monoaminergic cell populations (noradrenalin, serotonin)
whereas others report only dopamine degeneration e.g. [11] or
together with increased levels of serotonin [43]. PD patients show
multiple neuronal system degenerations [44]. Furthermore, it is
unknown whether the observed chronobiological alterations can
be attributed to direct or indirect consequences of a breakdown of
dopamine homeostatic regulation affecting the sleep-wake system
and/or the circadian oscillator system. At least some outputs of the
circadian control system appear to be conserved, since the con-
centration and rhythms of melatonin, cortisol and prolactin
secretion reportedly remain largely intact [45].
Inter-individual variability
The four monkeys showed a differential vulnerability to the
MPTP treatment, in agreement with previous studies [6,7,18]. All
three female cynomolgus showed highly similar early and long-
lasting non-motor alterations during and after CLD-MPTP
treatment. Despite inter-individual differences we clearly show
that all cases exhibited very early changes in both rest-activity
cycles and cognitive performances, virtually immediately after the
firsts MPTP administration and prior to clinical motor symptoms.
In case T the period of intoxication required to reach clinical
significance was nearly 3 to 5 times longer than for other cases.
The lower sensitivity of case T to MPTP at the doses and
frequency employed here (0.2 mg.kg
21 every 3–4 days) may have
allowed specific compensatory mechanisms that were distinct from
those in other cases, which however did not differentially affect the
expression of non-motor symptoms (here rest-activity cycle
alterations and cognitive deficits). In case T, cognitive difficulties
in the detour reaching task were stable during the MPTP
treatment but were practically undetectable after spontaneous
clinical recovery. We observed that case T learned the detour
reaching task more rapidly than other cases. In view of these
observations case T was also trained to a more complex delayed
response task (spatial working memory task with a delay of 10sec,
Figure S2) that revealed stable cognitive deficits throughout the
presymptomatic period and persistence after full clinical recovery.
These results are in agreement with those showing that the level of
cognitive deficits depends on task difficulty, in both parkinsonian
patients [46] and rhesus monkeys treated with MPTP [13].The
variability between subjects could originate from various factors
ranging from individual genetic susceptibilities to the treatment,
age, species or gender differences [6,18,47]. Although several
species (macaques, vervet monkeys) and both genders have been
used in previous experiments no comprehensive comparative
studies have been made with non-human primates. The issue of
variability is also illustrated by the fact that fully clinically
recovered animals can present DA cell loss that is equivalent to
those observed for severe symptomatic cases [6]. Similarly,
asymptomatic-recovered monkeys show similar changes in sub-
cortical/cortical aminergic levels compared to those observed for
symptomatic cases [48].
Here we show that the use of quantile analyses to equate the
different durations of each phase overcomes some aspects of
individual variability and allows a more rationalized behavioral
evaluation. Nevertheless the inter-variability observed in response
to treatment or for post-treatment recovery in the MPTP model is
clearly of value since it may help to better understand the
variability of human PS.
Compensatory mechanisms
The use of CLD-MPTP models potentially allows determina-
tion of the functional basis of the compensatory mechanisms
Figure 5. Quantile Analysis. Clinical Scores (A), behavioral performance (B, error rate) and measures on rest-activity rhythms representing intra-
daily stability (C, strength of coupling), relative amplitude (D, rhythm intensity) and variability (E, fragmentation) for case J (black), case T (dark grey),
case F (grey) and case L (light grey).
doi:10.1371/journal.pone.0023952.g005
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possibly involving more than one aminergic system [6,42,49]. Our
finding that chronobiological and cognitive symptoms persist in
motor recovered animals poses a number of questions concerning
the physiological status of motor-recovered animals. Along with
previous studies that have shown cognitive deficits during the
presymptomatic period, the present findings emphasize that the
full spectrum of deficits during this stage is more extensive than
previously thought. This kind of protocol (longitudinal and using
the CLD-MPTP model) aims at reaching deeper insights into the
presymptomatic period and should be further used to explore if
neurophysiological markers of sleep structure [11] or of perfor-
mance monitoring [50] can ultimately be used as reliable
diagnostic tools for ongoing PS in humans.
Supporting Information
Figure S1 Locomotor activity rhythms (monkey F): A.
48h double-plot actogram: activity presented over consecutive days
(each line is 48h) for the entire protocol. Daytime and night time
periods are delimited by white and black rectangles, respectively
(above actogram). Note the strong synchronization of activity at
lights-off and fragmentation of daytime activity with MPTP treat-
ment. B. 24h average locomotor activity profiles of 3 representative
weeks taken over different time-windows of the protocol (week
periods indicated on the left of profiles). Locomotor activity
rhythms (monkey L): C. 48h double-plot actogram and D. 24h
average locomotor activity profiles (average over 3 representative
weeks within the period indicated on the left). Note the clear
fragmentation and amplitude decrease of daytime activity with
MPTP intoxication. While we can observe a progressive return of
daytime activity after MPTP-Off, this is far from baseline levels and
moreover accompanied by a strong increase in night time activity.
(TIF)
Figure S2 Spatial memory task. A. Spatial delayed retrieval
task paradigm. The monkey is facing 3 wells with opaque cover;
first, wells are opened so that the monkey can see which one
contains the reward. Then an opaque screen is placed between
animal and wells during 10sec; after the delay the monkey had to
reach the correct well to obtain the reward. In case of error, the
trial start again until reward is found. Perseverance in incorrect
choices is carefully noted: incorrect trials for which the monkey
makes the same incorrect choice as in the previous trial. This task
evaluates the integrity of short term spatial memory. B. Clinical
score (up) and performances (down) of monkey T along the entire
protocol. Note the clear expression of frontal-like behavior
(perseverance, black bars) with MPTP intoxication and persistence
after MPTP-off. In B. stars correspond to statistical results of contrast with
control values (see material and method section); *: p,0.05, **: p,0.01,
.:
p,0.07 i.e. marginally significant.
(TIF)
Figure S3 Detour Task paradigm. In this task monkeys
have to reach a piece of fruit placed in a transparent box with only
one opened window. In direct trials (left), the opening is facing the
animal so that reach is straightforward; in detour trials (right), the
opening is not facing the monkey so that a detour has to be
planned before reaching the reward. This easy-to-learn and easy-
to-test task evaluates lack of inhibition, behavior dependent on the
integrity of frontal cortex, the dopaminergic system and DA
innervation of frontal cortex.
(TIF)
Table S1 Summary table of results. Behavioral data and
MPTP cumulated dose are shown for each monkey (columns) and
for the major periods of the follow-up study: control (CTR),
presymptomatic state (PMRS score ,5), symptomatic state
(PMRS score .5) and recovery period. -: not available.
(DOCX)
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